TCT 2019 | PARTNER 3: Obvious Short-Term Quality of Life Improvement, but What Happens Afterwards?

Courtesy of SBHCI.

Patients with severe aortic stenosis and low surgical risk showed decreased mortality, stroke, and heart failure hospitalization at one year with transcatheter aortic valve replacement compared with surgery. Improved quality of life may seem an obvious consequence, but until now that was mere speculation.

Highlights TCT 2019

This work, presented at the TCT 2019 Scientific Sessions and simultaneously published in JACC, analyzes precisely that: short- and long-term quality of life of patients who underwent transcatheter aortic valve replacement vs. surgery.

This analysis included 1000 low-risk patients with severe aortic stenosis who were randomized to balloon-expandable valve vs. surgery between 2016 and 2017.


Read also: TCT 2019 | EURO-CTO: Results at 3 Years of CTO Recanalization vs. Optimal Medical Treatment.


Quality of life was measured at baseline, 1, 6, and 12 months by means of the Kansas City Cardiomyopathy Questionnaire (KCCQ), SF-36, and EQ-5D.

At one month from the procedure, results showed that patients who underwent transcatheter aortic valve replacement had much better scores than patients who underwent surgery (p < 0.0001).

At 6 and 12 months, such difference remained in favor of the balloon-expandable valve, but the curves were closer, narrowing the gap (p < 0.04).

The ratio of patients with excellent results was higher with TAVR, both at 6 months (90.3% vs. 85.3%; p = 0.03) and at 12 months (87.3% vs. 82.8%; p = 0.07).

Conclusion

Patients with severe aortic stenosis and low surgical risk who undergo transcatheter aortic valve replacement with a balloon-expandable valve have better quality of life scores, both in the short and in the long term, compared with surgery.

Courtesy of SBHCI.

Link to the SBHCI publication HERE

partner3-tct2019

Original Title: PARTNER 3: Health Status Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Low Surgical Risk.

Author of the Original Article: Suzanne J. Baron.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...